Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  • The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
  • The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
  • Where available, URLs for the references have been provided.
  • The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
  • The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Author Guidelines


Online submission
The Journal of Electroceuticals in Mental Health will only consider manuscripts that are submitted through our online peer-review website: 


Once a manuscript is successfully submitted, the submitting author should expect to receive an email notification within hours. Only senior authors of a work who take complete scientific as well as financial responsibility of a submission may submit the work. Manuscripts cannot be submitted on behalf of the corresponding author by any agent other than the corresponding author's own office. All manuscripts should be submitted in Microsoft Word or RTF formatted files and should contain all embedded tif or eps formatted figures.

Cover Letter: The submitting author must accept responsibility for the following:

  • The submitting author has the written consent from all authors to submit the manuscript and that all authors accept complete responsibility for the contents of the manuscript.
  • The manuscript has not been previously published, or is not currently under consideration elsewhere, and that the work reported will not be submitted for publication elsewhere until a final decision has been made as to its acceptability by The Journal of Electroceuticals in Mental Health (note that posting of submitted material on a website is considered pre-publication).
  • The manuscript is truthful original work.



Please upload individual files of all manuscript material—do NOT upload a single PDF file containing all text, figure, and table files of your article. Once all individual files are uploaded to the site, the system will automatically create a single PDF proof for you and the peer-review process.

Peer Review Process

Format. Manuscripts that are not formatted strictly according to the guidelines described herein or in the guide for Online Submission will be administratively rejected without any peer review.

ScienceThe Journal of Electroceuticals in Mental Health can only accept highly competitive articles. All submissions, other than those in the News and Views track, are subject to peer review. 

Article Types

Critical Reviews:  Articles in this track should address late-breaking science in a focused area relevant neuromodulation in treating mental illnes and in mental health. Critical Reviews should range from 3,000 to 4,000 words (excluding a maximum of 50 references and figure legends) with at least 6 illustrations.

Technology Advances:  Covers novel technologies related to electroceutical product development or mental health research methodology.

News and Views:  Covers case observations of extraordinary significance and newsworthy developments in the use of electroceuticals in the mental health community. May include: review of patents and other relevant intellectual properties, business of electroceuticals, law, insurance, billing, global issues, ethics, quality control, special considerations and so on. News and Views articles should not exceed a total of 1,500 words, excluding a maximum of 9 references. Photos may be included as part of illustration.

Comprehensive Invited Reviews:  Written by invited authoritative experts.  Comprehensive Invited Reviews are to be between 5,000 and 7,500 words long (excluding a maximum of 150 references and figure legends) and must include at least 10 illustrations.  If you are an authoritative expert (senior investigator with long standing and extensive publication record) in a field relevant to the Journal and are interested in contributing a Comprehensive Invited Review article, please write to the Editor-in-Chief. These articles are intended to be full-length critical appraisals of topics that would be of long-term archival value. Textbook-style coverage is strongly discouraged. Emphasis should be placed on late-breaking advances and critical treatment.  The Journal of Electroceuticals in Mental Health dedicates a substantial amount of space to these articles. To ensure balanced treatment of any given subject, these articles are typically reviewed by several experts in that field. These experts are identified in the publication as Reviewing Editors unless they opt against it.



All accepted manuscripts will be reviewed for occurances potential plagiarism, and any notice of acceptance is considered conditional, pending the completion of a plagiarism review. If a high incidence of overlap in text is found, the Editor-in-Chief reserves the right to rescind the decision to accept the paper.  





Patients and Study Participants

All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit  http://www.icmje.org/about-icmje/faqs/icmje-recommendations/       

When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).

The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.

In addition, text and photographs should not reveal any identifying information unless it is essential for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.



Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.

Definitions of Scientific Misconduct

The Journal of Electroceuticals in Mental Health generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  •  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.

  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.

  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.

  • Material failure to comply with legislative and regulatory requirements affecting research: 
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.

  • Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.

  • Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.


Responding to Allegations of Possible Misconduct

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.


Copyright Agreement
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by The NeuroBiology Foundation, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

Upon acceptance of any manuscript, EACH author listed on a paper will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications, particularly the Copyright Agreement.


The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.


Type the entire manuscript, including figure legends, tables, and references, single-spaced using Microsoft Word. Leave 1-inch margins on all sides. Manuscripts should be written succinctly and should cite select references that are directly relevant.  For guidance on length of each article, see section on article types above. Manuscripts not following these length related guidelines will be subjected to administrative rejection.

Title page: Specify the type of article. Title page must list the full title of the article; author(s); all authors’ full affiliations; an abbreviated title for the running head (not to exceed 50 characters, including spaces); name and address of corresponding author, contact telephone, fax number, and e-mail address. Where necessary, identify each author’s affiliation by superscript numbers matched to the appropriate institution. Please list word count (excluding abstract, references, and figure legends).

Second page: Provide an abstract of no more than 250 words. For Review articles, the abstract should consist of the following sections: Significance, Recent Advances, Critical Issues, and Future Directions. For Technology Advances articles, the abstract should consist of the following sections: Objective, Approach, Results, Innovation, and Conclusion. For News and Views articles, the abstract does not need to be structured with headings. Submissions with abstracts longer than 250 words will not be considered for publication.

Following pages (Technology Advances): The abstract should be followed by the following sections: Introduction, Clinical Problem Addressed (even if it is basic science research, highlight what clinical problem is the work relevant to), Materials and Methods, Results (for Technology Advances track, provide schematic diagram of device as appropriate), Discussion, Innovation, Key Findings (present as itemized bullet list of 3-4 major findings), Acknowledgments and Funding Sources, Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends. Begin each of these sections on a separate page. The Innovation section cannot exceed 100 words and cannot be diffused. In 4-6 sentences it must summarize the current state of the field and then cite specific results reported to explain how this work helps to substantially advance the field. If the work has clinical significance, please be sure to highlight that. Do not regurgitate findings.

Following pages (Reviews): The abstract should be followed by a table of content that highlights the sections (1.0, 2.0) and sub-sections (e.g.  2.1, 2.1.1 etc). Each Review article must start with these three sections: 1.0 Scope and Significance (one paragraph on the scope of the review and its significance); 2.0 Translational Relevance (one paragraph); 3.0 Clinical Relevance (one paragraph). Each Review article must have both Relevance sections regardless of whether the article is translational (includes basic science) or clinical. Each of these paragraphs should not exceed 100 words. These sections may be followed by a Background or Overview section. The Discussion section should come next, which will encompass the majority of the text. At the end of the Review article, please include a Summary of one or two paragraphs, as well as an itemized list of Take-Home Messages. This list of messages will be presented as a sidebar in the final published version of your article, and is aimed at broad readership who may not be an expert in the subject. The Take-Home Messages will be followed by these required sections: Acknowledgments and Funding Sources, Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends.

Following pages (News and Views): The format for News and Views articles is flexible. The following sections are suggested but not required: IntroductionClinical Problem Addressed (highlight what clinical problem is the article relevant to), Discussion, Innovation, Summary, and Key Findings or Take-Home Messages. The article must end with the sections Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends.

A complete list of abbreviations (covering text as well as illustrations) arranged in alphabetical order must be provided at the end just before the References section.

Number pages (bottom-center) consecutively; the first author’s last name should appear on each page. The text should be clear and concise, conforming to accepted standards of English style and usage. Unfamiliar or new terms should be defined when first used (see section on Abbreviations, Symbols, and Terminology below). Jargon, clichés, and laboratory slang should not be used. All files to be uploaded for review must have the primary authors last name as part of the filename.

Author Disclosure and Ghostwriting Statement 

Immediately following the Acknowledgments and Funding Sources section, include a section entitled Author Disclosure and Ghostwriting. This text must be part of your actual manuscript file.  In this portion of the manuscript, authors must disclose commercial associations that might create a conflict of interest in connection with submitted manuscripts and must give credit to any ghostwriters involved in the writing of the manuscript.  This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at www.icmje.org/index.html#conflicts for further guidance. If there is nothing to disclose, the authors must state “No competing financial interests exist. The content of this article was expressly written by the author(s) listed. No ghostwriters were used to write this article.”


It is mandatory that all articles using microarray data analysis comply with the Minimum Information About Microarray Experiments (MIAME) standard (www.mged.org).


In accordance with the HUGO Gene Nomenclature Committee (HGNC), authors should obtain approval for new human and mouse gene symbols. Additional information on gene nomenclature guidelines is available from the HGNC (www.genenames.org.)


The Journal endorses the principles embodied in the Declaration of Helsinki and insists that all investigations involving humans be conducted in conformity with these principles. All animal experimentation reported must be conducted in conformity with internationally accepted principles. In describing surgical procedures, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed. All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. Editors are expected to reject articles in which evidence of the adherence to these principles is not apparent. They reserve the right to judge the appropriateness of the use of animals and humans in experiments. The Editors-in-Chief will adjudicate differences of opinion employing principles consistent with the content posted at: http://ethics.od.nih.gov/


Include in the manuscript a list of new or special abbreviations used in the article, with the spelled-out form of the definition. Internationally accepted biochemical abbreviations such as ADP, NADH, and pi do not need to be defined; other frequently used abbreviations need only to be defined at first mention. For commonly accepted abbreviations, word usage, symbols, etc., authors are referred to Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers (6th ed., 1994). Chemical and biochemical terms and abbreviations should be in accordance with the recommendations of the IUPAC system. IUB Combined Commission on Biochemical Nomenclature. Isotope specification should conform to the IUPAC system.


Authors should follow Webster’s Third New International Dictionary for spelling and compounding.


Journal policy is against inclusion of implicit or explicit promises that future work will be published.


Horizontal and vertical lines should not be used in the background of any line or bar graph. It is critically important that dead space within illustration be kept to a minimum. Single column wide illustrations should not exceed 7.5 cm in width. Use font size that is not too small and clearly legible. For illustrations that must be unavoidably wider, the maximum limit is 15 cm for width. Figure legend should be a part of the main body of the text.

The use of Tables is discouraged. When unavoidable, the title should be brief and informative. All explanatory matter, including explanation of abbreviations, should be in footnotes, not in the title. Horizontal and vertical lines should be omitted. Use Arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences. Table footnotes should be listed in order of their appearance and identified by consecutive superior lowercase letters (a, b, c, etc.).


Please follow these guidelines for submitting manuscripts:

  • Embed all art files into a Word or PDF document as high resolution tif or eps files.
  • Do NOT prepare art files in Word.
  • Line illustrations should be submitted at 900 dpi.
  • Halftones and color should be submitted at a minimum of 300 dpi.
  • Color art must be saved as CYMK–not RGB.
  • Black and white art must be submitted as grayscale–not RGB.

Additional Information About Art Files

Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format that is suitable for on-line publishing is to scan them using the below guidelines:

  • All files should be scanned at 100% size.
  • 300 dpi
  • Final color mode: cmyk.
  • Save file as .tif or .eps.



Submit high-quality digital copies using the Journal of Electroceuticals in Mental Health Online submission system. Figure legends should describe experimental conditions and all abbreviations used. Electrocardiograms, kymograms, and oscillograms should be prepared so that the cross- hatched background is eliminated. To avoid problems in processing, use non-photo, blue-ruled instead of black-ruled, recording paper for the originals.


Color publication of figures is encouraged. All figures that are submitted in color will appear in color in the online version of the Journal.


Authors are responsible for the accuracy of citations. References must be limited to directly pertinent published works or articles that have been accepted for publication. An abstract properly identified (Abstract) may be cited only when it is the sole source. Submitted articles can be cited in the text as “unpublished observations” but should not be included in the reference list (see below for further description). Works that have been accepted for publication in a journal should be included in the references list, indicating the journal in which it is to be published followed by “(in press)”. If you are using a referencing managing software you may use the style for Journal of Women’s Health. All references must be cited in the text using a superscript Arabic number. Arrange the reference list in numeric order as cited in the text. Note that for numbering purposes, references cited within a table or figure legend should be treated as if the citation occurred at the location where the table or figure is mentioned in the text. When there are more than six authors, list the first three followed by “et al.” Abbreviate journal names according to Medline. References should be presented in the following style: Journal articles: 1. Moldovan L, Irani K, Moldovan NI, Finkel T, Goldschmidt-Clermont PJ. The actin cytoskeleton reorganization induced by Rac1 requires the production of superoxide. Antioxid Redox Signal 1999;1:29–43.  Book: 2. Sen CK, Sies H, Baeuerle PA, eds. Antioxidant and Redox Regulation of Genes, 2nd ed. San Diego, CA: Academic Press, 2000.  Book section: 3. Masutani H, Ueno M, Ueda S, Yodoi J. Role of thioredoxin and redox regulation in oxidative stress response and signaling. In: Sen CK, Sies H, Baeuerle PA, eds. Antioxidant and Redox Regulation of Genes. San Diego, CA: Academic Press, 2000:298–310.  Web site:  Author/editor (if known) or page publisher. Title of page. Revision or copyright date, if available. URL Protocol:Site/Path/File (last access date). Example: 6. The American Gastroenterological Association. The RUC process. www.gastro.org/practice/coding/the-ruc-process (last accessed December 1, 2013).  References to government technical documents should be included only when the corresponding author ensures their availability. For style of citation of these documents, congress proceedings, etc., consult recent issues of the Journal. Citations such as “unpublished observations” or “personal communication” should not be included in the reference list but may be added in the text in parentheses or as a footnote. When data from an unpublished source are given, supply the researcher’s name and institution, and the year in which the research was conducted. It is assumed that in “personal communications,” the author has secured the written permission of the person cited.


The corresponding authors must accept full responsibility to return corrected galley proof within 5 days of receipt. Only corrections directly related to errors in typesetting will be allowed. Other changes will have to be approved by the Editor and are subject to being charged. If the corresponding author does not respond within 5 days of receipt of the galley proof, the manuscript may be dropped from publication schedule or published as is at the discretion of the publisher. If the corresponding author expects to be out of office during the time the galley proof is expected, the publisher should be provided with an alternate contact.


The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. A footnote to a reprinted table or to the legend of a reprinted figure should read, “Reprinted by permission from Jones et al.,” and list the appropriate reference. All permissions listings must be shown in the manuscript—they cannot be entered on proofs. Any fees or charges that are levied by other Publishers or copyright holders are the sole responsibility of the submitting authors(s)



The Journal of Electroceuticals in Mental Health is owned and published by The NeuroBiology Foundation, Inc.,  Telephone: (770)-337-2390; www.neurobiologyfoundation.org


Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.